Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NSIX -- Neuromedical Systems, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Chartgod who wrote (100)	7/5/1998 3:28:00 PM
From: David K.	Read Replies (1) \| Respond to of 137

It's hard to know what gong on here. There has been a small amount of insider buying lately. The stock is selling under book value and cash value. The revenues increased from last year. Their European strategy might be a key to their future. "Revenue from European operations increased from $280,000 in the first quarter of 1997 to $1,059,000 in the first quarter of 1998 reflecting the Company's continued implementation of its business strategy in Europe of selling and leasing PAPNET-on-Cyte(TM) systems directly to laboratory customers."